Ayala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report published on Wednesday morning. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of Ayala Pharmaceuticals stock opened at $0.05 on Wednesday. The stock has a 50 day moving average of $0.03 and a 200 day moving average of $0.04. The firm has a market capitalization of $1.92 million, a price-to-earnings ratio of -0.01 and a beta of 1.68. Ayala Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.78.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.